AI Article Synopsis
- Renal cell carcinoma (RCC) is a serious kidney cancer that typically doesn’t respond well to traditional chemotherapy, making early surgical intervention crucial for a cure.
- Advanced RCC treatment relies on targeted therapies, including tyrosine kinase inhibitors and immune checkpoint blockade, but not all patients can benefit from these options.
- The review emphasizes the importance of identifying biomarkers to predict how well RCC patients will respond to immune checkpoint blockade therapies.
Article Abstract
Renal cell carcinoma (RCC) is a highly aggressive neoplastic disease of the renal parenchyma that is characterized by an intrinsic resistance to cytotoxic chemotherapy; for this reason, curative treatment is only achieved through surgical intervention in its early stages. The successful treatment of advanced or metastatic RCC will require the combined use of novel targeted therapies such as tyrosine kinase inhibitors, vascular endothelial growth factor blockers and immune checkpoint blockade therapies. Unfortunately, not all patients are candidates for such treatments, and at present, it is not possible to predict a patient's therapeutic response or likelihood to develop treatment‑associated complications. The present review described the literature focusing on the use of biomarkers for predicting patients' responses to therapies that induce immune checkpoint blockade in RCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3892/or.2024.8823 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!